IR-MED Reports Positive Interim Results from U.S. Clinical Study of PressureSafe(TM) for Pressure Injury Assessment Across Diverse Skin Tones
PressureSafe™, IR-MED's lead product, demonstrated 94% sensitivity in assessing tissue at risk for pressure injuries prior to visible skin breakdownTechnology addresses longstanding disparities in skin assessment, particularly in patients with darker skin tonesResults presented at HCA Healthcare & Galen College of Nursing Research Day; additional data to be featured at a podium session at the 2025 ANCC Magnet/ANE Research SymposiumRosh Pina, Israel--(Newsfile Corp. - June 23, 2025) - As the U.S. commemorated Juneteenth, last week, IR-MED Inc
2025-06-23 8:30 AM EDT
IR-MED Awarded $500,000 Grant from the Israel Innovation Authority to Advance AI-Powered DiaSafe(TM) Device for Diabetic Foot Ulcer Assessment
DiaSafe™, IR-MED's second product, is being developed to provide safe, real-time optical readings of biomarkers for assessment of diabetic foot ulcers The most common cause of amputation, diabetic foot ulcers can be prevented with early assessment, improving patient care and healthcare economics in a $10 billion global treatment market $500,000 grant underscores continued confidence in IR-MED's noninvasive "Sensing the Invisible" technology platformRosh Pina, Israel--(Newsf
2025-05-05 8:30 AM EDT